Eli Lilly and Company (LLY)
Lillys sofetabart mipitecan receives U.S. FDAs Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
Lillys sofetabart mipitecan receives U.S. FDAs Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
📈 **POSITIVE** • Medium confidence analysis (79%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical